Featured Product
KD/KO Validated

Chk1 Polyclonal antibody

Name: Chk1 Polyclonal antibody
Brand: Proteintech
SKU: 10362-1-AP

Chk1 Polyclonal Antibody for FC, IF, IHC, WB,ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IHC, IF, FC,ELISA

Conjugate

Unconjugated

Publications

Review Product

Cat no : 10362-1-AP

Synonyms

CHEK1, Chk1

Validation Data Gallery

Filter:

AllWBIHCIFFC

WB analysis of mouse thymus using 10362-1-AP
mouse thymus tissue were subjected to SDS PAGE followed by western blot with 10362-1-AP (CHK1 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.
WB analysis of K-562 using 10362-1-AP
K-562 cells were subjected to SDS PAGE followed by western blot with 10362-1-AP (CHK1 antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.
WB analysis of HeLa using 10362-1-AP
HeLa cells were subjected to SDS PAGE followed by western blot with 10362-1-AP (CHK1 antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.
WB analysis of HeLa using 10362-1-AP
HeLa cells were subjected to SDS PAGE followed by western blot with 10362-1-AP (CHK1 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.
IHC staining of human lung cancer using 10362-1-AP
Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 10362-1-AP (CHK1 Antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).
IHC staining of human lung cancer using 10362-1-AP
Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 10362-1-AP (CHK1 Antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).
IHC staining of human lung cancer using 10362-1-AP
Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 10362-1-AP (CHK1 Antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).
IHC staining of human lung cancer using 10362-1-AP
Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 10362-1-AP (CHK1 Antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).
IF Staining of HepG2 using 10362-1-AP
Immunofluorescent analysis of HepG2 cells using 10362-1-AP (Chk1 antibody) at dilution of 1:25 and Rhodamine-Goat anti-Rabbit IgG.
FC experiment of HepG2 using 10362-1-AP
1X10^6 HepG2 cells were stained with 0.2ug CHK1 antibody (10362-1-AP, red) and control antibody (blue). Fixed with 90% MeOH blocked with 3% BSA (30 min). Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) with dilution 1:1000.

-/ -

Cat No. 10362-1-AP

Freight/Packing: -

Country/Region

Size/Concentration

Quantity

Proteintech Guarantee

Request bulk or custom quote

Chat with a team member

Tested Applications

Positive WB detected in	mouse thymus tissue, HeLa cells, K-562 cells
Positive IHC detected in	human lung cancer tissue **Note: suggested antigen retrieval with TE buffer pH 9.0; () Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0***
Positive IF detected in	HepG2 cells
Positive FC detected in	HepG2 cells

Recommended dilution

Application	Dilution
Western Blot (WB)	WB : 1:500-1:1000
Immunohistochemistry (IHC)	IHC : 1:50-1:500
Immunofluorescence (IF)	IF : 1:10-1:100
Flow Cytometry (FC)	FC : 0.20 ug per 10^6 cells in a 100 µl suspension
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Published Applications

KD/KO	See 1 publications below
WB	See 16 publications below
IHC	See 1 publications below

Product Information

10362-1-AP targets Chk1 in WB, IHC, IF, FC,ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity	human, mouse, rat
Cited Reactivity	human, mouse, rat
Host / Isotype	Rabbit / IgG
Class	Polyclonal
Type	Antibody
Immunogen	Chk1 fusion protein Ag0409
Full Name	CHK1 checkpoint homolog (S. pombe)
Calculated Molecular Weight	54 kDa
Observed Molecular Weight	50-55 kDa
GenBank Accession Number	BC004202
Gene Symbol	CHEK1
Gene ID (NCBI)	1111
Conjugate	Unconjugated
Form	Liquid
Purification Method	Antigen affinity purification
Storage Buffer	PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage Conditions	Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

In response to DNA damage, mammalian cells prevent cell cycle progression through the control of critical cell cycle regulators. CHK1 (synonym: CHEK1), a homolog of the Schizosaccharomyces pombe Chk1 protein kinase, is required for the DNA damage checkpoint. Human Chk1 protein is modified in response to DNA damage. In vitro Chk1 binds to and phosphorylate the dual-specificity protein phosphatases Cdc25A, Cdc25B, and Cdc25C, which control cell cycle transitions by dephosphorylating cyclin-dependent kinases. CHK1 can be autophosphorylated(PMID:22941630) and ubiquitinated (PMID:19276361). It has 3 isoforms produced by alternative splicing with the molecular weight of 54 kDa, 44 kDa and 50 kDa.

Protocols

Product Specific Protocols
WB protocol for Chk1 antibody 10362-1-AP	Download protocol
IHC protocol for Chk1 antibody 10362-1-AP	Download protocol
IF protocol for Chk1 antibody 10362-1-AP	Download protocol
FC protocol for Chk1 antibody 10362-1-AP	Download protocol

Standard Protocols
Click here to view our Standard Protocols

Publications

Species	Application	Title
human	WB	Nat Commun Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons. Authors - Andrew Best KD Validated View Article
	WB	Proc Natl Acad Sci U S A Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints. Authors - Navjotsingh Pabla View Article
human	WB	Oncotarget UBE2D3 gene overexpression increases radiosensitivity of EC109 esophageal cancer cells in vitro and in vivo. Authors - Xiaojia Gao View Article
human	WB	EBioMedicine High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. Authors - Xia Li View Article
human	WB	Cell Death Dis HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma. Authors - Xinying Zhao View Article
human	WB	Cell Death Dis PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT. Authors - Wen-Kai Shi View Article

Products

Applications

cGMP Proteins

Support

Services

Promotions

About Us

Antibodies

Immunoassays

Cytokines and Growth Factors

Nanobody-based Reagents

Supporting Tools and Reagents

Research Area

Chk1 Polyclonal antibody

Chk1 Polyclonal Antibody for FC, IF, IHC, WB,ELISA

Validation Data Gallery

WB analysis of mouse thymus using 10362-1-AP

WB analysis of K-562 using 10362-1-AP

WB analysis of HeLa using 10362-1-AP

WB analysis of HeLa using 10362-1-AP

IHC staining of human lung cancer using 10362-1-AP

IHC staining of human lung cancer using 10362-1-AP

IHC staining of human lung cancer using 10362-1-AP

IHC staining of human lung cancer using 10362-1-AP

IF Staining of HepG2 using 10362-1-AP

FC experiment of HepG2 using 10362-1-AP

Tested Applications

Recommended dilution

Published Applications

Product Information

Background Information

Protocols

Publications

Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons.

Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints.

UBE2D3 gene overexpression increases radiosensitivity of EC109 esophageal cancer cells in vitro and in vivo.

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.

HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma.

PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT.